Insulin Lispro (Humalog) Injectable Suppliers & Bulk Manufacturers
Available Forms: Vials/pens
Available Strengths: U-100, U-200
Reference Brands: Humalog, Admelog, Fiasp(US); Humalog, Fiasp(EU)
Category: Diabetes
Insulin Lispro (Humalog) is a rapid-acting insulin that quickly mimics natural insulin release post-meal. It lowers blood sugar rapidly, providing flexible dosing around mealtimes. Benefits include quick onset, precise glucose control, reduced post-meal hyperglycemia, and improved convenience for insulin therapy, essential for effective management of diabetes. Insulin Lispro (Humalog) injectable is available in Vials/pens and strengths such as U-100, U-200. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Insulin Lispro (Humalog) injectable is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Insulin Lispro (Humalog) injectable can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
Product Description:
Insulin Lispro (Humalog) is a rapid-acting insulin approved in the EU and US for post-meal blood glucose control. In the EU, Novo Nordisk’s Fiasp, a faster-acting version, is regulated by EMA with dossiers demonstrating safety, efficacy, and manufacturing quality. In the US, the FDA has approved Humalog and biosimilars like Admelog based on comprehensive clinical data, biosimilarity, and ongoing pharmacovigilance. Both regions require detailed regulatory dossiers for approval and post-marketing safety monitoring. For expert assistance with pharmaceutical dossiers and compliance, visit PharmaTradz, your trusted partner in regulatory solutions.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Insulin Lispro is used to improve blood sugar control in adults and children with diabetes mellitus, including both type 1 and type 2 diabetes. It is a rapid-acting insulin that helps to manage blood glucose levels after meals.
Insulin Lispro is a recombinant human insulin analogue produced using recombinant DNA technology in Escherichia coli bacteria. It differs from human insulin by the reversal of two amino acids—proline and lysine—at positions 28 and 29 on the B-chain, which allows it to act faster in the body.
The trade name for Insulin Lispro is Humalog.
Insulin Lispro (Humalog) is manufactured by Eli Lilly and Company.
The generic name of this product is Insulin Lispro.
The brand name of Insulin Lispro is Humalog.
Insulin Lispro is manufactured by Eli Lilly and Company, with production facilities located in the United States and several other countries, including France and Italy, depending on the regional supply chain.
Related Products
Pioglitazone Hydrochloride
Strength:
15 mg, 30 mg, 45 mg
Form: Tablets
Reference Brands: Actos (USA)
View Details
Nateglinide
Strength:
60 mg, 120 mg, 180 mg
Form: Tablets
Reference Brands: Starlix (USA)
View Details
Miglitol
Strength:
25 mg, 50 mg, 100 mg
Form: Tablets
Reference Brands: Glyset (USA), Diastabol (EU)
View Details
Sotagliflozin
Strength:
200 mg, 40mg
Form: Tablets
Reference Brands: Inpefa (USA), Zynquista (EU)
View DetailsQuick Response Guaranteed | Verified Suppliers
